Rare Disease Innovation in an Evolving Industry with Amgen’s Dr. Sumita Bhatta — Episode 207

In this episode, Ayesha speaks with Sumita Bhatta, MD, Vice President and Global Development Therapeutic Head of Rare Disease at Amgen.

In the conversation, Dr. Bhatta shares insights on how large pharmaceutical companies like Amgen are approaching innovation and patient-centricity in the rare disease space.

She also discusses the unique challenges and opportunities in developing therapies for small patient populations and how cross-functional collaboration drives progress in this complex field.

Dr. Bhatta is a board-certified medical oncologist with over a decade of experience in the biopharmaceutical industry serving multiple roles in research and development.

Dr. Bhatta received her undergraduate degree from UCLA and received both an MA in Applied Physiology and MD from the Rosalind Franklin University of Medicine and Science in Chicago, IL. She completed her internal medicine residency, hematology/oncology fellowship and a clinical pharmacology/pharmacogenomics fellowship at the University of Chicago.

Tune in to hear how Dr. Bhatta and her team are advancing innovation in rare disease drug development — and why big pharma’s role in this space matters more than ever.

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

If you want to have your organization featured on Xtalks, please email Ayesha Rashid at: [email protected]